OPKO Health Announces 2024 Annual Meeting of Stockholders on March 28

TL;DR

<b>OPKO Health will hold its 2024 Annual Meeting on March 28, 2024, to elect directors, increase authorized shares, vote on executive pay, and ratify auditor appointment.</b>

AI Summary

OPKO HEALTH, INC. (OPK) filed a Proxy Statement (DEF 14A) with the SEC on February 29, 2024. Annual Meeting scheduled for March 28, 2024, held virtually. Proposes to elect eleven director nominees. Seeks approval to increase authorized common stock from 1 billion to 1.25 billion shares. Will hold a non-binding advisory vote on executive compensation ('Say on Pay'). Seeks ratification of Ernst & Young LLP as independent auditor for FY2024.

Why It Matters

For investors and stakeholders tracking OPKO HEALTH, INC., this filing contains several important signals. The proposed increase in authorized shares from 1 billion to 1.25 billion could facilitate future fundraising or acquisitions. The 'Say on Pay' vote provides shareholders an advisory role in executive compensation, reflecting corporate governance practices.

Risk Assessment

Risk Level: low — OPKO HEALTH, INC. shows low risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would significantly alter the company's risk profile.

Analyst Insight

Stockholders should review the proxy materials to make informed decisions on director elections, share authorization, executive compensation, and auditor ratification.

Key Numbers

• 11 — Director Nominees (To be elected at the Annual Meeting)
• 1,000,000,000 — Current Authorized Shares (Common stock)
• 1,250,000,000 — Proposed Authorized Shares (Common stock)
• 2024 — Fiscal Year End (For auditor ratification)

Key Players & Entities

• OPKO Health, Inc. (company) — Registrant
• Ernst & Young LLP (company) — Independent registered public accounting firm
• 2024 (date) — Annual Meeting year
• March 28, 2024 (date) — Annual Meeting date
• February 13, 2024 (date) — Record date for voting
• February 29, 2024 (date) — Filing date

FAQ

Industry Context

OPKO Health operates in the pharmaceutical preparations industry, focusing on developing and commercializing diagnostics and treatments.

Regulatory Implications

This filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Evaluate the proposal to increase authorized shares and its potential implications.
3. Consider the advisory vote on executive compensation and cast an informed vote.

Key Dates

• 2024-03-28: Annual Meeting of Stockholders — Election of directors, approval of charter amendment, advisory vote on executive compensation, and auditor ratification.
• 2024-02-13: Record Date — Determines stockholders entitled to vote at the Annual Meeting.
• 2024-02-29: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is a proxy statement filing for the annual meeting and does not contain comparative financial data from a previous filing.

Key Financial Figures

• $0.01 — f the Company's common stock, par value $0.01 per share ("common stock"), that may be

Filing Documents

• opk20240216_def14a.htm (DEF 14A) — 802KB
• capvnetincrs.jpg (GRAPHIC) — 99KB
• capvrevrs.jpg (GRAPHIC) — 99KB
• capvtsrrs.jpg (GRAPHIC) — 94KB
• opkoproxycardfinal-1rs.jpg (GRAPHIC) — 139KB
• opkoproxycardfinal-2rs.jpg (GRAPHIC) — 125KB
• sr.jpg (GRAPHIC) — 3KB
• 0001437749-24-006106.txt (&nbsp;) — 1571KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table contains information regarding the beneficial ownership of our common stock, which is our only outstanding class of voting securities, as of February 29, 2024 held by (i) each stockholder known by us to beneficially own more than 5% of the outstanding shares of common stock; (ii) our directors and director nominees; (iii) our Named Executive Officers as defined in the paragraph preceding the Summary Compensation Table contained elsewhere in this proxy statement and our current executive officers; and (iv) all current directors and executive officers as a group. Except where noted, all holders listed below have sole voting power and investment power over the shares beneficially owned by them. Unless otherwise noted, the address of each person listed below is c/o OPKO Health, Inc., 4400 Biscayne Blvd., Miami, FL 33137. Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity in the table below, all shares subject to options or other derivative securities held by such person or entity were deemed outstanding if such securities are currently exercisable, or exercisable or would vest based on applicable vesting conditions within 60 days of February 29, 2024 . These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity. Amount and Nature Name and Address of Beneficial Percentage of Beneficial Owner Class of Security Class** Directors and Named Officers: Phillip Frost, M.D. Common Stock 244,

View Full Filing

View this DEF 14A filing on SEC EDGAR